Increased Prolactin Levels During Reserpine Treatment of Hypertensive Patients
- LCDR Peter A. Lee, MC;
- LCDR Michael R. Kelly, MC;
- CDR John D. Wallin, MC
Abstract
Serum prolactin levels are significantly greater among hypertensive patients receiving reserpine as compared to levels six weeks after discontinuing the treatment (P <.005). This association between regular, longterm reserpine use and greater prolactin levels may be clinically significant, since an increased incidence of breast cancer has been reported among hypertensive patients receiving reserpine.
(JAMA 235:2316-2317, 1976)
Footnotes
-
The opinions and assertions contained herein are those of the authors and are not to be construed as official or as reflecting the views of the Navy Department or the naval service at large.
-
Reprint requests to Publications Office, Clinical Investigation Center, Naval Regional Medical Center, Oakland, CA 94627 (Dr Lee).
